Taken together, we hypothesize that the oncogenic potential of SLC25A51 in AML may be attributed to its capacity to transfer NAD+ into mitochondria, thereby enhancing the activity of the NAD-dependent enzymes SIRT3, SIRT4, and SIRT5 located in mitochondria, which ultimately promotes the malignant proliferation of AML cells (50). Here, SIRT3 is linked to acute myeloid leukemia.